Having trouble accessing articles? Reset your cache.

GammaDelta spins out Adaptate to focus on antibody therapies

As GammaDelta nears bringing its T cell therapies to the clinic, it’s spinning out Adaptate to focus on the development of its γδ antibody-based programs.

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502;

Read the full 295 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE